Cargando…
Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy
PURPOSE: The body mass index (BMI) is commonly used as a simple indicator of obesity; patients with early-stage breast cancer who are obese (OB) per BMI measurements have been shown to have high postoperative recurrence and low survival rates. On the other hand, it has been shown that lymphocytes pr...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529767/ https://www.ncbi.nlm.nih.gov/pubmed/34670511 http://dx.doi.org/10.1186/s12885-021-08857-7 |
_version_ | 1784586535820066816 |
---|---|
author | Takada, Koji Kashiwagi, Shinichiro Asano, Yuka Goto, Wataru Ishihara, Sae Morisaki, Tamami Shibutani, Masatsune Tanaka, Hiroaki Hirakawa, Kosei Ohira, Masaichi |
author_facet | Takada, Koji Kashiwagi, Shinichiro Asano, Yuka Goto, Wataru Ishihara, Sae Morisaki, Tamami Shibutani, Masatsune Tanaka, Hiroaki Hirakawa, Kosei Ohira, Masaichi |
author_sort | Takada, Koji |
collection | PubMed |
description | PURPOSE: The body mass index (BMI) is commonly used as a simple indicator of obesity; patients with early-stage breast cancer who are obese (OB) per BMI measurements have been shown to have high postoperative recurrence and low survival rates. On the other hand, it has been shown that lymphocytes present in the vicinity of malignant growths that are involved in the tumors’ immune responses influence the efficacy chemotherapy. Therefore, we hypothesized that OB patients with breast cancer have a lower density of tumor-infiltrating lymphocytes (TILs), which may influence the therapeutic effect of preoperative chemotherapy (POC). In this study, we measured pretreatment BMI and TILs in patients with breast cancer who underwent POC, examined the correlations between these two factors, and retrospectively analyzed their therapeutic outcomes and prognoses. METHODS: The participants in this study were 421 patients with breast cancer who underwent surgical treatment after POC between February 2007 and January 2019. The patient’s height and weight were measured before POC to calculate the BMI (weight [kg] divided by the square of the height [m(2)]). According to the World Health Organization categorization, patients who weighed under 18.5 kg/m(2) were classified as underweight (UW), those ≥18.5 kg/m(2) and > 25 kg/m(2) were considered normal weight (NW), those ≥25 kg/m(2) and < 30 kg/m(2) were overweight (OW), and those ≥30 kg/m(2) were OB. The TILs were those lymphocytes that infiltrated the tumor stroma according to the definition of the International TILs Working Group 2014. RESULTS: The median BMI was 21.9 kg/m(2) (range, 14.3–38.5 kg/m(2)); most patients (244; 64.5%) were NW. Among all 378 patients with breast cancer, the TIL density was significantly lower in OB than in NW and OW patients (vs. NW: p = 0.001; vs. OW: p = 0.003). Furthermore, when examining patients with each breast cancer type individually, the OS of those with TNBC who had low BMIs was significantly poorer than that of their high-BMI counterparts (log rank p = 0.031). CONCLUSIONS: Our data did not support the hypothesis that obesity affects the tumor immune microenvironment; however, we showed that being UW does affect the tumor immune microenvironment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08857-7. |
format | Online Article Text |
id | pubmed-8529767 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85297672021-10-25 Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy Takada, Koji Kashiwagi, Shinichiro Asano, Yuka Goto, Wataru Ishihara, Sae Morisaki, Tamami Shibutani, Masatsune Tanaka, Hiroaki Hirakawa, Kosei Ohira, Masaichi BMC Cancer Research PURPOSE: The body mass index (BMI) is commonly used as a simple indicator of obesity; patients with early-stage breast cancer who are obese (OB) per BMI measurements have been shown to have high postoperative recurrence and low survival rates. On the other hand, it has been shown that lymphocytes present in the vicinity of malignant growths that are involved in the tumors’ immune responses influence the efficacy chemotherapy. Therefore, we hypothesized that OB patients with breast cancer have a lower density of tumor-infiltrating lymphocytes (TILs), which may influence the therapeutic effect of preoperative chemotherapy (POC). In this study, we measured pretreatment BMI and TILs in patients with breast cancer who underwent POC, examined the correlations between these two factors, and retrospectively analyzed their therapeutic outcomes and prognoses. METHODS: The participants in this study were 421 patients with breast cancer who underwent surgical treatment after POC between February 2007 and January 2019. The patient’s height and weight were measured before POC to calculate the BMI (weight [kg] divided by the square of the height [m(2)]). According to the World Health Organization categorization, patients who weighed under 18.5 kg/m(2) were classified as underweight (UW), those ≥18.5 kg/m(2) and > 25 kg/m(2) were considered normal weight (NW), those ≥25 kg/m(2) and < 30 kg/m(2) were overweight (OW), and those ≥30 kg/m(2) were OB. The TILs were those lymphocytes that infiltrated the tumor stroma according to the definition of the International TILs Working Group 2014. RESULTS: The median BMI was 21.9 kg/m(2) (range, 14.3–38.5 kg/m(2)); most patients (244; 64.5%) were NW. Among all 378 patients with breast cancer, the TIL density was significantly lower in OB than in NW and OW patients (vs. NW: p = 0.001; vs. OW: p = 0.003). Furthermore, when examining patients with each breast cancer type individually, the OS of those with TNBC who had low BMIs was significantly poorer than that of their high-BMI counterparts (log rank p = 0.031). CONCLUSIONS: Our data did not support the hypothesis that obesity affects the tumor immune microenvironment; however, we showed that being UW does affect the tumor immune microenvironment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08857-7. BioMed Central 2021-10-20 /pmc/articles/PMC8529767/ /pubmed/34670511 http://dx.doi.org/10.1186/s12885-021-08857-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Takada, Koji Kashiwagi, Shinichiro Asano, Yuka Goto, Wataru Ishihara, Sae Morisaki, Tamami Shibutani, Masatsune Tanaka, Hiroaki Hirakawa, Kosei Ohira, Masaichi Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy |
title | Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy |
title_full | Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy |
title_fullStr | Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy |
title_full_unstemmed | Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy |
title_short | Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy |
title_sort | clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529767/ https://www.ncbi.nlm.nih.gov/pubmed/34670511 http://dx.doi.org/10.1186/s12885-021-08857-7 |
work_keys_str_mv | AT takadakoji clinicalverificationofbodymassindexandtumorimmuneresponseinpatientswithbreastcancerreceivingpreoperativechemotherapy AT kashiwagishinichiro clinicalverificationofbodymassindexandtumorimmuneresponseinpatientswithbreastcancerreceivingpreoperativechemotherapy AT asanoyuka clinicalverificationofbodymassindexandtumorimmuneresponseinpatientswithbreastcancerreceivingpreoperativechemotherapy AT gotowataru clinicalverificationofbodymassindexandtumorimmuneresponseinpatientswithbreastcancerreceivingpreoperativechemotherapy AT ishiharasae clinicalverificationofbodymassindexandtumorimmuneresponseinpatientswithbreastcancerreceivingpreoperativechemotherapy AT morisakitamami clinicalverificationofbodymassindexandtumorimmuneresponseinpatientswithbreastcancerreceivingpreoperativechemotherapy AT shibutanimasatsune clinicalverificationofbodymassindexandtumorimmuneresponseinpatientswithbreastcancerreceivingpreoperativechemotherapy AT tanakahiroaki clinicalverificationofbodymassindexandtumorimmuneresponseinpatientswithbreastcancerreceivingpreoperativechemotherapy AT hirakawakosei clinicalverificationofbodymassindexandtumorimmuneresponseinpatientswithbreastcancerreceivingpreoperativechemotherapy AT ohiramasaichi clinicalverificationofbodymassindexandtumorimmuneresponseinpatientswithbreastcancerreceivingpreoperativechemotherapy |